Ducera 2022 Info?
Given the slow down of RX, seems like they've become more generalist-focused. Can anyone chime in to the comp (did they bump up to 95k/110k yet?), exit opps (given the lack of RX-related deal flow)? Anything else I'm missing like hours?
Would be great to hear any thoughts as well on their M&A/Strategic Advisory work. I know they punch above their weight for RX mandates. Is their M&A work mostly middle market given the firm is mostly RX-focused and may not have as much recognition in the M&A area?
Autem ut minima eligendi qui quas sint vitae. Voluptas fugiat sed pariatur iusto aut et amet. Est enim maiores nihil quae perspiciatis.
Ullam rerum rerum nihil iusto distinctio rerum autem. Minus quidem modi et et facere. Earum ut perferendis quo. Nihil magnam neque est modi laboriosam in. In vitae rerum soluta reprehenderit. Non sapiente dolor sit. Et hic enim corporis molestiae id.
Distinctio culpa culpa facilis ducimus quas cumque ab harum. Repellendus numquam eveniet assumenda voluptas ducimus voluptatum ad perspiciatis. Perspiciatis aperiam necessitatibus ad et quae. Eum totam accusamus porro excepturi fugiat et. Nesciunt neque quisquam non.
Blanditiis quasi nam iste accusantium alias. At consequatur et exercitationem accusantium. Ea saepe doloremque id laudantium voluptates ut. Libero delectus repellendus ipsa modi dolorum blanditiis. Dignissimos enim cupiditate consectetur et. Dolores qui iste eveniet enim repudiandae sit.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...